Phathom Pharmaceuticals annual operating margin
2023
2024
2025
Phathom Pharmaceuticals Operating Margin Growth & History (PHAT)
Phathom Pharmaceuticals's operating margin was −91.36% for fiscal 2025.
View full Phathom Pharmaceuticals company overviewPhathom Pharmaceuticals annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −91.36% | +410.82 pp |
| 2024 | 2024-12-31 | −502.18% | +24030.37 pp |
| 2023 | 2023-12-31 | −24,532.55% | — |
Phathom Pharmaceuticals quarterly operating margin
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5.34% | +146.36 pp |
| Q1 2026 | 2026-03-31 | −26.55% | +249.98 pp |
| Q4 2025 | 2025-12-31 | −10.29% | +190.01 pp |
| Q3 2025 | 2025-09-30 | −30.85% | +402.10 pp |
| Q2 2025 | 2025-06-30 | −151.69% | +903.74 pp |
| Q1 2025 | 2025-03-31 | −276.53% | +3382.15 pp |
| Q4 2024 | 2024-12-31 | −200.30% | +10045.30 pp |
| Q3 2024 | 2024-09-30 | −432.95% | — |
| Q2 2024 | 2024-06-30 | −1,055.43% | — |
| Q1 2024 | 2024-03-31 | −3,658.68% | — |
| Q4 2023 | 2023-12-31 | −10,245.60% | — |
Phathom Pharmaceuticals operating margin trends
Across the available reported history, Phathom Pharmaceuticals's operating margin increased from −502.18% to −91.36%, a change of +410.82 percentage points. The latest reported quarter, Q2 2026, shows −5.34%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phathom Pharmaceuticals filings at SEC.gov ↗